9-Deazaadenosine--a new potent antitumor agent

Area of Science:

• Biochemistry
• Pharmacology
• Oncology

Background:

• Novel purine analog 9-deazaadenosine (9-DAA) exhibits potent anticancer properties.
• Investigating the efficacy and mechanisms of 9-DAA against various human solid tumors.

Purpose of the Study:

• To evaluate the in vitro and in vivo anticancer activity of 9-deazaadenosine.
• To explore the synergistic effects of 9-DAA with adenosine deaminase inhibitors and nucleoside transport inhibitors.

Main Methods:

• In vitro cytotoxicity assays against nine human solid tumor cell lines.
• In vivo studies using antithymocyte serum (ATS)-immunosuppressed mice bearing pancreatic carcinoma (DAN).
• High-performance liquid chromatography (HPLC) for nucleotide profiling and incorporation studies of radiolabeled nucleosides.

Main Results:

• 9-DAA demonstrated potent inhibition with IC50 values ranging from 1.1 to 8.5 X 10(-8)M against tumor cell lines.
• 2'-deoxycoformycin (dCF) potentiated 9-DAA activity against ovarian carcinoma (MR) by approximately 10-fold.
• In vivo, 9-DAA (0.4 mg/kg/day) reduced pancreatic tumor weights by 50%; p-nitrobenzyl-6-thioinosine (NBMPR) enhanced antitumor activity by reducing host toxicity.

Conclusions:

• 9-deazaadenosine is a promising anticancer agent with broad-spectrum activity against human solid tumors.
• Combination therapies involving 9-DAA with dCF or NBMPR may enhance therapeutic efficacy and reduce toxicity.